Orthofix Appoints Dr. Anthony F. Martin to its Board of Directors
LEWISVILLE, Texas -- December 3, 2013
Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced the
appointment of Anthony F. Martin, PhD to its Board of Directors, effective
immediately. Dr. Martin has more than 25 years of international experience in
managing life science businesses in both executive and non-executive roles.
Randy Thurman, Chairman of the Board of Orthofix, commented, "Coupled with the
recent announcement of Kathy Regan and me joining the board, Dr. Martin's
addition marks a new era for Orthofix. In addition to the revitalized board,
Brad Mason, Orthofix's CEO, rejoined the company earlier this year and has put
in place a seasoned and motivated leadership team, many of whom are new to
Orthofix or their roles. In addition to resolving the financial restatement in
a timely manner, we are focused on reinvigorating both product and clinical
development strategies, establishing leadership in our strategic business
units and creating long-term value for our shareholders."
Dr. Martin has a Doctorate in Immunology from the University of Manchester
Medical School and a first class Honors degree in Applied Chemistry from the
University of Huddersfield. He began his career with Proctor & Gamble UK
before moving to Amersham International, subsequently GE, in marketing and
business development roles. He has significant experience in fundraising and
building medical technology companies, including in chief executive officer
and chairman roles.
Anthony Martin PhD
Dr. Martin has more than 25 years of international experience in managing life
science businesses in both executive and non-executive roles. He is currently
the Non-Executive Chairman of Immunodiagnostics Systems Holdings plc, Sphere
Medical Holding plc, and Phico Therapeutics Ltd, and a Non-Executive Director
of Abcam plc. He gained a doctorate in Immunology from the University of
Manchester Medical School and a first class honors degree in Applied Chemistry
from Huddersfield University. Dr. Martin has previously served as chief
executive officer at a number of international life sciences and diagnostic
businesses including British Bio-Technology Products ltd, Celsis International
plc, AZUR Environmental, the molecular biology division of Invitrogen
Corporation, and Molecular Probes Inc. He has also previously served as the
Chairman of NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc. and
as a board member of Prelude Trust plc and Invitrogen Corporation. In
addition, he previously served on the scientific advisory Board of Agilent
The Orthofix board believes that Dr. Martin’s extensive experience as an
international operational CEO, combined with his deep knowledge of the UK
institutional shareholder base for medical companies and UK financing matters,
will add significant value to the board as the Company seeks to grow its UK
and European operations and market presence. The board also believes that his
experience serving with both UK and US public companies will bring added depth
and a cross-border perspective with board governance matters.
Orthofix International N.V. is a diversified, global medical device company
focused on developing and delivering innovative orthopedic solutions that
drive value for patients, surgeons, and providers. Orthofix’s products are
widely distributed around the world to surgeons and patients via Orthofix’s
sales representatives and its subsidiaries, and via collaborations with other
leading orthopedic product companies. In addition, Orthofix is collaborating
on R&D activities with leading research and clinical organizations such as the
Musculoskeletal Transplant Foundation and Education Foundation and Texas
Scottish Rite Hospital for Children. For more information about Orthofix,
please visit www.orthofix.com.
Orthofix International N.V.
Mark Quick, 214-937-2924
Director of Investor Relations
Press spacebar to pause and continue. Press esc to stop.